Le rétatrutide de LLY montre des résultats d'essais mitigés

Score

0,4

Vélocité

▲ 1,0

Articles

6

Sources

2

Résumé

Un article appartient à ce récit s'il traite des résultats mitigés de l'essai clinique de retatrutide d'Eli Lilly and Company (LLY) pour le traitement du diabète de type 2.

Articles Liés

Jim Cramer Believes Eli Lilly’s “Weight Loss Pill Will Be a Blockbuster”

Yahoo Finance · Avr 05, 2026

Mixed

Should You Buy Eli Lilly Stock Before April 10?

Nasdaq · Mar 22, 2026

Mixed

Eli Lilly and Company (LLY) Announces Positive Topline Results From the Phase 3 ADorable-1 Trial

Yahoo Finance · Mar 22, 2026

Bearish

RBC Capital Sees Eli Lilly’s (LLY) Retatrutide as Key Growth Driver despite Mixed Trial Results

Yahoo Finance · Mar 21, 2026

Mixed

Sources

Jim Cramer Believes Eli Lilly’s “Weight Loss Pill Will Be … Yahoo Finance

1 Reason Eli Lilly Stock Is Still a Buy Nasdaq

Should You Buy Eli Lilly Stock Before April 10? Nasdaq

Eli Lilly and Company (LLY) Announces Positive Topline Results From … Yahoo Finance

RBC Capital Sees Eli Lilly’s (LLY) Retatrutide as Key Growth … Yahoo Finance

Chronologie

Dernière mise à jour Mar 21, 2026